Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells

Aim: LS-007 is a CDK Inhibitor, which exhibits potent antitumor activity against chronic lymphocytic leukemia and ovarian Cancer cells. In this study, we further evaluated the antitumor activity of LS-007 alone and in combination with a Bcl-2 Inhibitor ABT-199 in acute leukemia (AL) cells.

Methods: Cell viability was detected using resazurin assay, and cell Apoptosis was examined using Annexin V/PI double staining and flow cytometry. The inhibition of LS-007 on kinases was evaluated with the mobility shift assay or ELISA. The expression of relevant signaling molecules was assessed using Western blotting and RT-PCR. Primary lymphocytes from patients with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) were separated using Ficoll-Paque PLUS.

Results: LS-007 inhibited the proliferation of 6 AL cell lines with IC₅₀ values of 100-200 nmol/L, and decreased the survival of ALL and AML patient-derived lymphocytes with mean LD₅₀ value of 67 and 102 nmol/L, respectively. In kinase assays in vitro, LS-007 was more selective for the CDK family, inhibiting CDK2, CDK9, CDK1 and CDK4 at low nanomolar concentrations. In HL-60 and CCRF-CEM cells, LS-007 (0.1-0.4 μmol/L) dose-dependently induced cell Apoptosis predominantly through CDK9 inhibition-related dephosphorylation at the ser2 residue of RNA pol II and the corresponding depletion of anti-apoptotic proteins, especially Mcl-1 and XIAP. LS-007 (0.2 and 0.4 μmol/L) also induced cell Apoptosis in the patient-derived lymphocytes. In HL-60, CCRF-CEM and Molt-4 cells, combined application of LS-007 with ABT-199 (1 or 2 μmol/L) markedly increased cell Apoptosis with a maximal decrease in the XIAP levels as compared with either drug used alone.

Conclusion: CDK Inhibitor LS-007 potently inhibits the established human AL cell lines and primary AL blasts, and it also shows remarkable synergy with Bcl-2 Inhibitor ABT-199.